- Home
- ZYME vs DNTH Comparison
ZYME vs DNTH Comparison
Compare ZYME & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- DNTH
- Stock Information
- Founded
- ZYME 2003
- DNTH 2015
- Country
- ZYME United States
- DNTH United States
- Employees
- ZYME N/A
- DNTH N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- ZYME Health Care
- DNTH Health Care
- Exchange
- ZYME Nasdaq
- DNTH Nasdaq
- Market Cap
- ZYME 1.2B
- DNTH 1.4B
- IPO Year
- ZYME 2017
- DNTH N/A
- Fundamental
- Price
- ZYME $16.46
- DNTH $36.21
- Analyst Decision
- ZYME Strong Buy
- DNTH Strong Buy
- Analyst Count
- ZYME 7
- DNTH 11
- Target Price
- ZYME $22.00
- DNTH $65.44
- AVG Volume (30 Days)
- ZYME 889.7K
- DNTH 496.6K
- Earning Date
- ZYME 11-06-2025
- DNTH 11-05-2025
- Dividend Yield
- ZYME N/A
- DNTH N/A
- EPS Growth
- ZYME N/A
- DNTH N/A
- EPS
- ZYME N/A
- DNTH N/A
- Revenue
- ZYME $134,481,000.00
- DNTH $3,078,000.00
- Revenue This Year
- ZYME $99.52
- DNTH N/A
- Revenue Next Year
- ZYME N/A
- DNTH N/A
- P/E Ratio
- ZYME N/A
- DNTH N/A
- Revenue Growth
- ZYME 116.21
- DNTH N/A
- 52 Week Low
- ZYME $9.03
- DNTH $13.37
- 52 Week High
- ZYME $19.98
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- ZYME 36.30
- DNTH 58.59
- Support Level
- ZYME $17.27
- DNTH $32.56
- Resistance Level
- ZYME $19.98
- DNTH $37.47
- Average True Range (ATR)
- ZYME 0.76
- DNTH 1.69
- MACD
- ZYME -0.27
- DNTH 0.12
- Stochastic Oscillator
- ZYME 11.48
- DNTH 75.72
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.